3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Breast
4
Gastrointestinal
3
Head & Neck
2
Genitourinary
2
Thoracic
1
CNS
1
Conditions
Brain Neoplasms
3
Paraganglioma, Extra-Adrenal
2
Neoplasms
2
Glioma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Meningeal Carcinomatosis
1
Melanoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Medullary
1
Biliary Tract Neoplasms
1
Interventions
Filgrastim
12
Carboplatin
10
Paclitaxel
9
Peripheral Blood Stem Cell Transplantation
7
Cyclophosphamide
7
Ifosfamide
6
Temozolomide
5
Cisplatin
5
pembrolizumab
4
Nivolumab
4
Gemcitabine
4
Etoposide
4
Docetaxel
4
fludarabine
3
Thiotepa
3
Specimen Handling
3
Psychiatric Rehabilitation
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Immunologic Techniques
3
Fluorodeoxyglucose F18
3
Flow Cytometry
3
Bevacizumab
3
Amifostine
3
ulixertinib
2
trametinib
2
sargramostim
2
sapanisertib
2
pegfilgrastim
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
lenvatinib
×
CNS
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts